Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clofarabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Clofarabine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-003592-42 Sponsor Protocol Number: CLOFARABINE_UC Start Date*: 2023-11-27
    Sponsor Name:Medical University of Vienna
    Full Title: Clofarabine Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study
    Medical condition: Advanced urothelial carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001588-78 Sponsor Protocol Number: SPON CU 125 Start Date*: 2005-06-13
    Sponsor Name:Cardiff University
    Full Title: AML16 Pilot Trial: A Phase1/2 Trial to assess the feasibility of combining Clofarabine with daunorubicin and Daunorubicin + Clofarabine with Mylotarg in older patients with Acute Myeloid Leukaemia ...
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000880 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009457-13 Sponsor Protocol Number: StudyITCC020&I-BFMRelapsedAML Start Date*: 2009-07-30
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
    Medical condition: Relapsed/refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066638 Acute myeloid leukemia progression LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001172-21 Sponsor Protocol Number: CLO05908 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Japan K.K.
    Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010826-20 Sponsor Protocol Number: 2008_40 Start Date*: 2009-05-15
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: A phase I dose escalation study of clofarabine given in combination with multi-agent therapy for remission induction in pediatric patients with acute lymphoblastic leukemia in first relapse or refr...
    Medical condition: Traitement de la leucémie aigue lymphoblastiqsue
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001174-18 Sponsor Protocol Number: CLO21800205 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001853-27 Sponsor Protocol Number: BIOV-111 Start Date*: 2005-10-19
    Sponsor Name:Bioenvision Limited
    Full Title: A Phase II, Open-Label Study of Clofarabine in Paediatric Patients with Refractory / Relapsed Acute Lymphoblastic Leukaemia
    Medical condition: Relapsed or refractory acute lymphoblastic leukaemia (ALL) in children
    Disease: Version SOC Term Classification Code Term Level
    8.0 10050281 Lowe
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000142-34 Sponsor Protocol Number: ITCC-092/IST11028 Start Date*: 2020-09-15
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092
    Medical condition: Relapsed or refractory pediatric acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004527-35 Sponsor Protocol Number: BIOV-121 Start Date*: 2005-05-06
    Sponsor Name:Bioenvision Limited
    Full Title: A PHASE II TRIAL OF CLOFARABINE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FOR WHOM INTENSIVE CHEMOTHERAPY IS NOT CONSIDERED SUITABLE
    Medical condition: Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000880 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004487-39 Sponsor Protocol Number: CM-001 Start Date*: 2008-11-25
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Spontaneous monocentric study phase II: salvage therapy with clofarabine in combination with other cytotoxic agentsfor the treatment of resistent leukemia in children
    Medical condition: Acute Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000830 Acute leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005374-31 Sponsor Protocol Number: GIMEMA AML1107 Start Date*: 2008-12-29
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO
    Full Title: An open label phase II trial of Clofarabine and Temsirolimus in older patients with relapsed or refractory Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed or refractory Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017347-33 Sponsor Protocol Number: Clofarabine Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000880 Acute myeloid leukaemia PT
    12.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005798-36 Sponsor Protocol Number: HOVON100ALL/EORTC06083 Start Date*: 2009-08-31
    Sponsor Name:HOVON Foundation
    Full Title: Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
    Medical condition: Primary previously untreated B or T-lineage ALL (excluding ALL with mature B-cell phenotype, but including Philadelphia positive or BCR-ABL positive ALL) or previously untreated T-LBL
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10043028 T-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002288-14 Sponsor Protocol Number: HM1006 Start Date*: 2009-02-10
    Sponsor Name:University of Birmingham
    Full Title: Phase I Dose Escalation Study of Clofarabine and Liposomal Daunorubicin in Childhood and Adolescent AML
    Medical condition: Paediatric patients (6 months to 18 years) diagnosed with AML who are refractory to front line therapy, early first relapse (less than 1 year from diagnosis) and second and subsequent relapse patie...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10066764 Acute myeloid leukaemia progression LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011613-24 Sponsor Protocol Number: HOVON102AML/SAKK30/09 Start Date*: 2010-01-25
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously ...
    Medical condition: - a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or - a diagnosis of refractory anemia with excess of blasts (RAEB) and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054592 Refractory anemia with an excess of blasts LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066353 Treatment related acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022584-35 Sponsor Protocol Number: TUD-BRIDGE-046 Start Date*: 2011-11-25
    Sponsor Name:Dresden Universtity of Technology
    Full Title: Clofarabine salvage therapy in patients with relapsed or refractory AML The BRIDGE Trial
    Medical condition: Patients with AML >40 years of age with untreated relapse or refractory disease after a minimum of one standard induction therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060557 Acute myelocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021719-18 Sponsor Protocol Number: KS-2009-003 Start Date*: 2011-12-02
    Sponsor Name:Hannover Medical School
    Full Title: Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA)
    Medical condition: Patients with acute myeloid leukemia (AML) and high risk for induction failure
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004912-28 Sponsor Protocol Number: EORTC06061 Start Date*: 2012-02-17
    Sponsor Name:European Organisation for Research and Treatment on Cancer
    Full Title: Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukem...
    Medical condition: Previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012758-18 Sponsor Protocol Number: COALL09-05-04 Start Date*: 2010-09-09
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to ≤ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001043-19 Sponsor Protocol Number: CLO-34100405 Start Date*: 2008-09-24
    Sponsor Name:Genzyme Europe BV
    Full Title: Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have...
    Medical condition: Acute Myelogenous (Myeloid) Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 17:29:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA